China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2014 2Q14 New Subscribers Reached 15,928

2Q14 Revenue Up 10.3% YOY to RMB141.6 Million

2Q14 Operating Income Up 19.7% YOY to RMB56.3 Million

Conference Call to be Held November 15, 2013 at 8:00 a.m. ET

HONG KONG, Nov. 14, 2013 /PRNewswire-FirstCall/ -- China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced its preliminary unaudited financial results for the second quarter and first half of fiscal year 2014, which ended September 30, 2013.

Second Quarter of Fiscal 2014 Highlights

  • Revenues for the second quarter of fiscal 2014 increased by 10.3% to RMB141.6 million ($23.1 million) from RMB128.5 million in the prior year period.
  • New subscriber sign-ups and accumulated subscriber base were 15,928 and 343,170, respectively.
  • Gross profit increased by 12.7% to RMB114.3 million ($18.7 million) from RMB101.4 million in the prior year period.
  • Gross margin was 80.7%, compared to 78.9% in the prior year period.
  • Operating income increased by 19.7% to RMB56.3 million ($9.2 million) from RMB47.0 million in the prior year period.
  • Interest expense amounted to RMB16.5 million ($2.7 million), which was largely attributable to the convertible notes issued to KKR China Healthcare Investment Limited ("KKR") and Golden Meditech Holdings Limited ("Golden Meditech").
  • Net income attributable to the Company's shareholders increased by 0.8% to RMB24.9 million ($4.1 million) from RMB24.7 million in the prior year period, after taking into account higher income tax expense in the second quarter.
  • Operating cash flow for the quarter amounted to RMB121.0 million ($19.8 million), after taking into account the coupon payment made to the Company's convertible note holder.

First Half of Fiscal 2014 Highlights

  • Revenues for the first half of fiscal 2014 increased by 10.9% to RMB270.4 million ($44.2 million) from RMB243.8 million in the prior year period.
  • New subscriber sign-up reached 31,188 and accumulated subscriber base expanded to 343,170.
  • Gross profit increased by 13.6% to RMB218.5 million ($35.7 million) from RMB192.3 million in the prior year period.
  • Operating income increased by 11.7% to RMB102.2 million ($16.7 million) from RMB91.4 million in the prior year period.
  • Interest expense amounted to RMB31.2 million ($5.1 million), compared to RMB24.3 million in the prior year period.
  • Net income attributable to the Company's shareholders amounted to RMB57.8 million ($9.4 million), compared to RMB55.8 million in the prior year period.
  • Operating cash flow for the first half of fiscal 2014 was RMB229.6 million ($37.5 million), after taking into account the coupon payment made to the Company's convertible note holders.

"We are glad that our second quarter performance continued to track management's expectations with moderate sequential growth in new subscriber numbers, as the overall markets began to transition away from the Dragon year after-effect. During the second quarter, we continued to build brand awareness and emphasize service quality in our business. This aligns with our premium pricing initiative, backed by our AABB accreditation, that began in April this year," stated Ms. Ting Zheng, Chief Executive Officer of China Cord Blood Corporation.

Summary - The Second Quarter and First Half Ended September 30, 2012 and 2013


Three Months Ended September 30,

Six Months Ended September 30,



2012


2013


2012


2013

(in thousands)


RMB


RMB


US$


RMB


RMB


US$

Revenues


128,462


141,635


23,143


243,792


270,356


44,176

Gross Profit


101,405


114,275


18,672


192,346


218,504


35,703

Operating Income


47,044


56,290


9,198


91,442


102,170


16,694

Net Income Attributable to the Company's

Shareholders


24,695


24,904


4,069


55,788


57,810


9,446

Earnings per Ordinary Shares 
- Basic1 and Diluted (RMB/US$)


0.34


0.33


0.05


 

0.75


0.73


0.12














Revenue Breakdown (%)













Processing Fees


76.4%


71.6%




 

75.9%


70.6%



Storage Fees


23.6%


28.4%




 

24.1%


29.4%
















New Subscribers (persons)


18,491


15,928




 

34,951


31,188



Total Accumulated Subscribers (persons)


274,705


 

343,170




 

274,705


343,170
















[1] The terms of the convertible notes issued to KKR and Golden Meditech provide each party with the ability to participate in any excess cash dividend. Therefore, the calculation of basic EPS has taken into consideration the effect of such participating rights of RMB0.01($0.002) and RMB0.06($0.01) for the three months and six months ended September 30, 2013, respectively.

Summary - Selected Cash Flow Statement Items



Three Months Ended


Six Months Ended



September 30, 2013


September 30, 2013

(in thousands)


RMB


US$


RMB


US$

Net cash provided by operating activities


120,969


19,766


229,623


37,521

Net cash used in investing activities


(17,531)


(2,865)


(56,891)


(9,296)

Net cash provided by financing activities


5,578


911


2,336


381

Second Quarter of Fiscal 2014 Financial Results

REVENUES. Revenues increased by 10.3% to RMB141.6 million ($23.1 million) in the second quarter of fiscal 2014 from RMB128.5 million in the prior year period, driven mainly by higher pricing implemented since the previous quarter and the expansion in the Company's accumulated subscriber base, overcoming the year-over-year declines in new subscriber numbers due to the Dragon year after-effect.

Revenues generated from storage fees increased to RMB40.2 million ($6.6 million), up 32.7% from RMB30.3 million in the prior year period. Because of the increased accumulated subscriber base, revenue from storage fees accounted for 28.4% of total revenues, compared to 23.6% in the prior year period.

Revenues generated from processing fees in this quarter were RMB101.4 million ($16.5 million), up modestly from RMB98.2 million in the prior year period as pricing increases countered the impact of year-over-year declines in new subscriber numbers. 15,928 new subscriber sign-ups were recorded during the second quarter of fiscal 2014, representing a 13.9% year-over-year decrease but a 4.4% sequential increase. Revenues generated from processing fees accounted for 71.6% of total revenues, compared to 76.4% in the prior year period.

GROSS PROFIT. Gross profit for the second quarter of fiscal 2014 increased by 12.7% to RMB114.3 million ($18.7 million) from RMB101.4 million in the prior year period, as the benefits of economies of scale and higher price levels outweighed higher raw material costs. Gross margin was 80.7%, compared to 78.9% in the prior year period.

OPERATING INCOME. Operating income for the second quarter increased 19.7% to RMB56.3 million ($9.2 million) compared to RMB47.0 million in the prior year period. Operating margin improved to 39.7% from 36.6% in the prior year period as a result of higher gross margin and effective cost controls. Depreciation and amortization expenses for the second quarter were RMB8.7 million ($1.4 million), compared to RMB8.3 million in the prior year period.

Research and Development Expenses. Research and development expenses, which have been stable in the last few quarters, were RMB2.3 million ($0.4 million).

Sales and Marketing Expenses. Sales and marketing expenses for the second quarter amounted to RMB27.6 million ($4.5 million), compared to RMB23.5 million in the prior year period. The increase in sales and marketing expenses continued to correlate with the increase in revenue. Aside from higher staff costs, additional expenses were incurred for the marketing effort in preparation for the large scale Zhejiang market launch. However, management continued to monitor sales and marketing expenses and maintained consistent level of cost efficiency through cost cutting and prudent spending. As a result, sales and marketing expenses as a percentage of revenue decreased to 19.5% of revenues from 22.1% in the first quarter of the current fiscal year.

General and Administrative Expenses. General and administrative expenses were stable at RMB28.0 million ($4.6 million), compared to RMB29.0 million in the prior year period and RMB27.4 million in the first quarter of fiscal 2014. As a percentage of revenue, general and administrative expenses decreased to 19.8% compared to 22.6% in the prior year period and 21.3% in the first quarter of fiscal 2014.

OTHER INCOME AND EXPENSES

Interest Expense. Interest expense increased to RMB16.5 million ($2.7 million) from RMB14.1 million in the prior year period. The increase was largely attributable to the convertible note issued to Golden Meditech in the third quarter of fiscal 2013, offset in part by the capitalization of interest expense for the Company's in-progress construction of new facilities. Interest expense capitalized in the second quarter of fiscal 2014 amounted to RMB6.8 million ($1.1 million). No interest expense was capitalized in the prior year period.

NET INCOME ATTRIBUTABLE TO THE COMPANY'S SHAREHOLDERS. As the increase in income before tax was partially eroded by the increase in income tax expense, net income attributable to the Company's shareholders for the second quarter of fiscal 2014 increased by 0.8% to RMB24.9 million ($4.1 million) from RMB24.7 million in the prior year period. Net margin for the second quarter of fiscal 2014 was 17.6%. 

EARNINGS PER SHARE. The terms of the convertible notes issued to KKR and Golden Meditech provide each party with the ability to participate in any Excess Cash Dividend2. Therefore, the calculation of basic and diluted EPS has taken into consideration the effect of such participating rights of RMB0.01 ($0.002). Basic and diluted earnings per ordinary share for the second quarter of fiscal 2014 were RMB0.33 ($0.05).

LIQUIDITY. As of September 30, 2013, the Company had cash and cash equivalents of RMB1,669.4 million ($272.8 million) compared to RMB1,494.1 million as of March 31, 2013. The Company had total debt of RMB814.8 million ($133.1 million) as of September 30, 2013. Operating cash flow for the quarter amounted to RMB121.0 million ($19.8 million), after taking into account the coupon payment made to the Company's convertible note holder.

Ms. Zheng concluded, "The management continued to closely monitor the market impact of our upward pricing adjustment, and we are encouraged by the improvement in the number of new subscriber sign-ups which suggests the market has slowly adapted to the new pricing levels. At the same time, our capacity expansion in Guangdong and new facility development in Zhejiang are both well under way.  With the new facilities coming on-line by the end of the current fiscal year, we will be able to truly flex our marketing muscle and further penetrate the Guangdong market and the largely untapped Zhejiang market."

[2] "Excess Cash Dividend" means any cash dividend to holders of shares that, together with all other cash dividends previously paid to holders of shares in the same financial year, exceeds, on a per share basis, an amount equal to the interest that has accrued and shall accrue at 7% in such financial year divided by the number of shares into which the note is convertible at the conversion price then in effect on the relevant record date.

First Half of Fiscal 2014 Financial Results

For the first half of fiscal year 2014, total revenues increased by 10.9% to RMB270.4 million ($44.2 million) from RMB243.8 million in the prior year period. The increase was largely attributable to the implementation of the Company's new service pricing and the expansion of the Company's accumulated subscriber base to 343,170 subscribers, which partially offset the decrease in new subscriber numbers. Revenues from processing fees and storage fees grew by 3.1% and 35.4%, respectively. Gross profit increased by 13.6% to RMB218.5 million ($35.7 million) from RMB192.3 million in the prior year period. Operating income increased by 11.7% to RMB102.2 million ($16.7 million) from RMB91.4 million in the prior year period. Net income attributable to the Company's shareholders amounted to RMB57.8 million ($9.4 million). Basic and diluted earnings per share attributable to ordinary shares were RMB0.73 ($0.12). Net cash provided by operating activities in the first half of fiscal 2014 was RMB229.6 million ($37.5 million).

Conference Call

The Company will host a conference call at 8:00 a.m. ET on Friday, November 15, 2013 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session. Interested parties may access the audio webcast through the Company's IR website at http://ir.chinacordbloodcorp.com. A replay of the webcast will be accessible two hours after the conference call and available for three weeks at the same URL link above. Listeners may also access the call by dialing 1-631-514-2526 or 1-855-298-3404 for US callers or +852-5808-3202 for Hong Kong callers, access code: 5266601.

About China Cord Blood Corporation

China Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit our website at http://www.chinacordbloodcorp.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or the Company's future financial performance. The Company has attempted to identify forward-looking statements by terminology including "anticipates", "believes", "expects", "can", "continue", "could", "estimates", "intends", "may", "plans", "potential", "predict", "should" or "will" or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this press release is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company expectations are as of the date this press release is issued, and the Company does not intend to update any of the forward-looking statements after the date this press release is issued to confirm these statements to actual results, unless required by law.

The forward-looking statements included in this press release are subject to risks, uncertainties and assumptions about the Company's businesses and business environments. These statements reflect the Company's current views with respect to future events and are not a guarantee of future performance. Actual results of the Company's operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: continued compliance with government regulations regarding cord blood banking in the People's Republic of China, or PRC and any other jurisdiction in which the Company conducts its operations; changing legislation or regulatory environments in the PRC and any other jurisdiction in which the Company conducts its operations; the acceptance by subscribers of the Company's different pricing and payment options and reaction to the introduction of the Company's premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; the existence of a significant shareholder able to influence and direct the corporate policies of the Company; credit risks affecting the Company's revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company's ability to effectively manage its growth, including implementing effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of industry developments affecting issuers that have pursued a "reverse merger" with an operating company based in China, as well as general economic conditions; compliance with restrictive debt covenants under our senior convertible notes; and other relevant risks detailed in the Company's filings with the Securities and Exchange Commission in the United States.

This announcement contains translations of certain Renminbi amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to U.S. dollars as of and for the periods ending September 30, 2013 were made at the noon buying rate of RMB6.1200 to $1.00 on September 30, 2013 in the City of New York for cable transfers in Renminbi per U.S. dollar as certified for customs purposes by the Federal Reserve Bank of New York. China Cord Blood Corporation makes no representation that the Renminbi or U.S. dollar amounts referred to in this press release could have been or could be converted into U.S. dollars or Renminbi, at any particular rate or at all.

For more information, please contact:

China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com

ICR, Inc.
Mr. William Zima
Tel: (+86) 10-6583-7511
U.S. Tel: (646) 405-5185
Email: William.zima@icrinc.com

 

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

As of March 31 and September 30, 2013




March 31,


September 30,



2013


2013



RMB


RMB


US$



(in thousands except share data)








ASSETS                                                                                           










Current assets










Cash and cash equivalents



1,494,099



1,669,380



272,775

Accounts receivable, less allowance for doubtful accounts










   (March 31, 2013: RMB14,112; September 30, 2013: RMB16,082)



73,076



80,559



13,163

Inventories



10,265



16,832



2,751

Prepaid expenses and other receivables



11,602



14,844



2,425

Debt issuance costs



3,678



3,606



589

Deferred tax assets



5,454



5,985



978

Total current assets



1,598,174



1,791,206



292,681

Property, plant and equipment, net



468,272



520,169



84,995

Non-current prepayments



212,633



208,188



34,018

Non-current accounts receivable, less allowance for doubtful accounts










   (March 31, 2013: RMB36,361; September 30, 2013: RMB38,346)



249,370



236,064



38,572

Inventories



39,730



42,933



7,015

Intangible assets, net



125,170



122,860



20,075

Available-for-sale equity securities



88,404



169,699



27,729

Other investment



189,129



189,129



30,903

Debt issuance costs



11,667



9,630



1,574

Deferred tax assets



3,727



1,114



182

Total assets



2,986,276



3,290,992



537,744











LIABILITIES










Current liabilities










Bank loan



50,000



60,000



9,804

Accounts payable



9,890



8,779



1,434

Accrued expenses and other payables



84,006



64,942



10,611

Deferred revenue



172,328



181,428



29,645

Amounts due to related parties



11,241



720



118

Income tax payable



4,983



2,206



360

Deferred tax liabilities



-



1,300



212

Total current liabilities



332,448



319,375



52,184

Convertible notes



751,781



754,807



123,334

Non-current deferred revenue



530,258



665,226



108,697

Other non-current liabilities



107,158



133,954



21,888

Deferred tax liabilities



23,168



24,938



4,075

Total liabilities



1,744,813



1,898,300



310,178


EQUITY










Shareholders' equity of China Cord Blood Corporation






Ordinary shares










- US$0.0001 par value, 250,000,000 shares authorized,
   73,140,147 shares issued, and 73,003,248 shares outstanding
   as of March 31, 2013 and September 30, 2013, respectively



50



50



8

Additional paid-in capital



798,221



798,221



130,429

Treasury stock, at cost










   (March 31, 2013 and September 30, 2013: 136,899 shares,

   respectively)



(2,815)



(2,815)



(460)

Accumulated other comprehensive income



18,256



111,408



18,204

Retained earnings



423,420



481,230



78,633

Total equity attributable to China Cord Blood Corporation



1,237,132



1,388,094



226,814

Non-controlling interests



4,331



4,598



752

Total equity



1,241,463



1,392,692



227,566

Total liabilities and equity



2,986,276



3,290,992



537,744

 

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

For the Three Months and Six Months ended September 30, 2012 and 2013




Three months ended September 30,


Six months ended September 30,



2012


2013


2012


2013



RMB


RMB


US$

RMB


RMB


US$



(in thousands except share data)













Revenues                              



128,462



141,635



23,143


243,792



270,356



44,176

Direct costs



(27,057)



(27,360)



(4,471)


(51,446)



(51,852)



(8,473)

Gross profit



101,405



114,275



18,672


192,346



218,504



35,703

Operating expenses


















Research and development



(1,860)



(2,310)



(377)


(4,123)



(4,833)



(790)

Sales and marketing



(23,517)



(27,633)



(4,515)


(42,737)



(56,057)



(9,160)

General and administrative



(28,984)



(28,042)



(4,582)


(54,044)



(55,444)



(9,059)

Total operating expenses



(54,361)



(57,985)



(9,474)


(100,904)



(116,334)



(19,009)

Operating income



47,044



56,290



9,198


91,442



102,170



16,694

Other expense, net


















Interest income



3,859



4,312



705


7,188



8,494



1,388

Interest expense



(14,089)



(16,461)



(2,690)


(24,265)



(31,219)



(5,101)

Exchange gain/(loss)



41



69



11


51



(55)



(9)

Dividend income



-



-



-


2,420



8,722



1,425

Others



(1,002)



514



84


(766)



1,044



171

Total other expense, net



(11,191)



(11,566)



(1,890)


(15,372)



(13,014)



(2,126)

Income before income tax



35,853



44,724



7,308


76,070



89,156



14,568

Income tax expense



(8,466)



(19,706)



(3,220)


(14,801)



(31,079)



(5,078)

Net income



27,387



25,018



4,088


61,269



58,077



9,490

Income attributable to non-controlling interests



(2,692)



(114)



(19)


(5,481)



(267)



(44)

Net income attributable to China Cord Blood

   Corporation's shareholders



24,695



24,904



4,069


55,788



57,810



9,446



















Net income per share:


















Attributable to ordinary shares


















- Basic



0.34



0.33



0.05


0.75



0.73



0.12

- Diluted



0.34



0.33



0.05


0.75



0.73



0.12



















Other comprehensive income












- Net effect of foreign currency translation, net

   of nil tax



(1,007)



2,789



456


(2,424)



9,594



1,568

- Net unrealized gain/(loss) in available-for-sale

   equity securities, net of nil tax



2,624



59,220



9,676


(19,950)



83,558



13,653

Comprehensive income



29,004



87,027



14,220


38,895



151,229



24,711



















Comprehensive income attributable to non-

   controlling interests



(2,672)



(114)



(19)


(5,459)



(267)



(44)

Comprehensive income attributable to China 

   Cord Blood Corporation's shareholders



26,332



86,913



14,201


33,436



150,962



24,667

SOURCE China Cord Blood Corporation



RELATED LINKS
http://www.chinacordbloodcorp.com
http://ir.chinacordbloodcorp.com

More by this Source

Best of Content We Love 2014 


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.